Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

John Sheppard,1 Mark Bergmann,2 Barry A Schechter,3 Jodi Luchs,4 Abayomi Ogundele,5 Paul Karpecki6 1Virginia Eye Consultants, Norfolk, VA, USA; 2Apex Eye, Cincinnati, OH, USA; 3Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 4Florida Vision Institute, West Palm Beach, FL, USA; 5Medical...

Descripción completa

Detalles Bibliográficos

Autores principales:	Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Dove Medical Press 2021-01-01
Colección:	Clinical Ophthalmology
Materias:	cyclosporine a dry-eye disease keratoconjunctivitis sicca otx-101
Acceso en línea:	https://www.dovepress.com/phase-3-efficacy-worse-eye-analysis-and-long-term-safety-evaluation-of-peer-reviewed-article-OPTH
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!